References
- Creticos P S, Peters S P, Adkison R M, Jr, et al. Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. N Engl J Med 1984; 310: 1625
- Wang D, Clement P, Smitz J, Derde M-P. Concentrations of chemical mediators in nasal secretions after nasal allergen challenges in atopic patients. Eur Arch Otorhinolaryngol 1995; 252(Suppl 1)S40
- Okuda M, Watase T, Mezawa A, Liu C M. The role of leukotriene D4 in allergic rhinitis. Ann Allergy 1988; 60: 537
- Ferreri N R, Howland W C, Stevenson D D, Spiegel-Berg H L. Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. Am Rev Respir Dis 1988; 137: 847
- Kohi F, Miyagawa H, Agrawal D K, Bewtra A K, Townley R G. Generation of leukotriene B4 and C4 from granulocytes of normal controls, allergic rhinitis, and asthmatic subjects. Ann Allergy 1990; 65: 228
- Henderson W R, Jr. Role of leukotrienes in asthma. Ann Allergy 1994; 72: 272
- Cloud M L, Enas G C, Kemp J, et al. A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma. Am Rev Respir Dis 1989; 140(5)1336
- Spector S L, Smith L J, Glass M, the Accolate™ Asthma Trialists Group. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994; 150: 618
- Barnes N C, Pujet J-C, on behalf of an International Study Group. Pranlukast, a novel leukotriene receptor antagonist: Results of the first European, placebo-controlled, multicentre clinical study in asthma. Thorax 1997, (in press)
- Israel E, Conn J, Dube L, et al, for the Zikuton Clinical Trial Group. Effect of treatment with Zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. JAMA 1996; 275: 931
- Taniguchi Y, Tamura G, Honma M, et al. The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. J Allergy Clin Immunol 1993; 92: 507
- O'Shaughnessy T C, Georgiou P, Howland K, Barnes N. The effect of pranlukast, an oral leukotriene antagonist, on leukotriene D4 (LTD4) challenge in normal male subjects. Thorax 1997, (in press)
- Wenzel S E. Asthma as an inflammatory disease. Ann Allergy 1994; 72: 261
- Yamamoto H, Nagata M, Kuramitsu K, et al. Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078. Am J Respir Crit Care Med 1994; 150: 254
- Fujimura M, Sakamoto S, Kamio Y, Matsuda T. Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma. Respir Med 1993; 87: 133
- Taki P, Suzuki R, Tori K, et al. Reduction of the severity of bronchial hyperresponsiveness by the novel leukotriene antagonist 4-oxo-8-[4-(4-phenylbutoxy)benzoylamino]-2-(tetrazol-5-yl)-4H-1-benzopy-ran hemihydrate. Drug Res 1994; 44: 330
- Nakagawa N, Obata T, Kobayashi T, et al. In vivo pharmacologic profile of ONO-1078: A potent, selective and orally active peptide leukotriene (LT) antagonist. Jpn J Pharmacol 1992; 60: 217